Abstract
Dolutegravir (DTG) is a preferred drug for initial treatment of human immunodeficiency virus type 1 infection. We present next-generation sequencing analysis of integrase genotypes during a period of virologic failure in a treatment-naive man who initiated tenofovir disoproxil fumarate/emtricitabine plus DTG.
Publication types
-
Case Reports
-
Research Support, N.I.H., Extramural
MeSH terms
-
Antiretroviral Therapy, Highly Active
-
Drug Resistance, Viral*
-
Genotype
-
HIV Infections / drug therapy*
-
HIV Integrase Inhibitors / therapeutic use*
-
HIV-1 / drug effects*
-
HIV-1 / enzymology
-
HIV-1 / genetics
-
Heterocyclic Compounds, 3-Ring / therapeutic use*
-
Humans
-
Integrases / genetics*
-
Male
-
Middle Aged
-
Mutation
-
Oxazines
-
Piperazines
-
Pyridones
-
Sequence Analysis, DNA
-
Treatment Failure
Substances
-
HIV Integrase Inhibitors
-
Heterocyclic Compounds, 3-Ring
-
Oxazines
-
Piperazines
-
Pyridones
-
dolutegravir
-
Integrases